
    
      This is an open label interventional Phase IIa proof of concept clinical trial designed in
      two phases separated by a washout period of 6 weeks (Â± 2 weeks) , to evaluate the TTR
      stabilization activity of SOM0226 in healthy volunteers (wild type), TTR-FAP patients and
      asymptomatic carriers.

        -  Phase A (24 hours): SOM0226 single dose

        -  Phase B (32 hours): SOM0226 multiple dose
    
  